Related Experiment Video

Updated: Aug 26, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Emerging therapies for vascular dementia and vascular cognitive impairment

Timo Erkinjuntti1, Gustavo Román, Serge Gauthier

  • 1Helsinki University Central Hospital, Helsinki, Finland.

Stroke
|March 6, 2004
PubMed

Insights

Vascular cognitive impairment (VCI) and vascular dementia (VaD) treatments show promise. Managing cerebrovascular disease risk factors like hypertension can prevent dementia and improve cognitive function.

Area of Science:

  • Neurology
  • Geriatrics
  • Cardiovascular Medicine

Background:

  • Cerebrovascular disease (CVD) and ischemic brain injury are leading causes of dementia and cognitive decline in older adults.
  • CVD exacerbates cognitive loss in Alzheimer disease (AD).

Purpose of the Study:

  • To review progress in understanding and treating vascular cognitive impairment (VCI) and vascular dementia (VaD).
  • To highlight therapeutic strategies for cognitive and behavioral deficits associated with VCI and VaD.

Main Methods:

  • Review of clinical trials and therapeutic interventions for VCI and VaD.
  • Analysis of pharmacological treatments, including cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists.
  • Emphasis on primary and secondary stroke prevention strategies.

Main Results:

  • Cholinesterase inhibitors (donepezil, galantamine) improve cognition, behavior, and daily living in VaD and AD with CVD.
  • Memantine stabilized VaD progression compared to placebo.
  • Stroke prevention, particularly hypertension and hyperlipidemia control, reduces VaD incidence.

Conclusions:

  • Effective symptomatic and preventive treatments for VCI and VaD are advancing.
  • Early recognition of VCI and addressing vascular risk factors can significantly decrease dementia incidence globally.
Abstract

More Related Videos

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...